In addition, we performed survival analysis including OS, PFI (progression‐free interval) and DSS (disease‐specific survival) and found that the expression of MAP3K1 was negatively associated with the prognosis of glioma (Figure 2C–E). This evidence concerns the gene MAP3K1 and central nervous system cancer.